Tests elecoglipron against placebo in adults with type 2 diabetes using insulin
Tests elecoglipron, compared with a placebo, in adults with type 2 diabetes on insulin.
Plain-language title generated from the registry record
Registry title: A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
Key facts
- Where
- Aurora, Brooklyn, Cary, Decatur, DeLand, Doral, Houston, Little Rock, Memphis, Morehead City, Myrtle Beach, Ocoee, Potomac, Renton, Round Rock, Sacramento, and San Antonio, United StatesSee the 17 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes who already take insulin and other glucose-lowering medicine. It compares elecoglipron with placebo.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Type 2 diabetes for at least 90 days before screening, with HbA1c from ≥ 7% (53 mmol/mol) to ≤ 10.5% (91 mmol/mol).
- Earlier treatment
- Stable treatment with background insulin and other glucose-lowering medicine. Stable body weight for 90 days before screening.
- Biomarker or test result
- HbA1c of ≥ 7% (53 mmol/mol) to ≤ 10.5% (91 mmol/mol); body mass index (BMI) of ≥ 23 kg/m2 at screening
Main reasons for not taking part
- Type 1 diabetes, other secondary forms of diabetes, or a history of ketoacidosis or hyperosmolar coma
- More than one episode of severe low blood sugar in the 180 days before screening, or hypoglycemia unawareness
- History of acute or chronic pancreatitis
- Severe heart failure (NYHA IV)
- Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
Read by machine on 9 November 2026.
Where in United States
- AuroraAurora, United StatesNot yet recruiting
- BrooklynBrooklyn, United StatesNo longer taking part
- CaryCary, United StatesNot yet recruiting
- DecaturDecatur, United StatesNot yet recruiting
- DeLandDeLand, United StatesNo longer taking part
- DoralDoral, United StatesNot yet recruiting
- HoustonHouston, United StatesNot yet recruiting
- Little RockLittle Rock, United StatesNot yet recruiting
- MemphisMemphis, United StatesNot yet recruiting
- Morehead CityMorehead City, United StatesNot yet recruiting
- Myrtle BeachMyrtle Beach, United StatesNot yet recruiting
- OcoeeOcoee, United StatesTaking people
- PotomacPotomac, United StatesNot yet recruiting
- RentonRenton, United StatesNot yet recruiting
- Round RockRound Rock, United StatesNot yet recruiting
- SacramentoSacramento, United StatesNot yet recruiting
- San AntonioSan Antonio, United StatesNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07664553EU 2025-523935-20-00
- Record updated
- 4 August 2026
- Original description
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus (T2DM), treated with a background insulin and other background glucose-lowering medication(s)Read full original descriptionShow less
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin (Eluminate-3)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus (T2DM), treated with a background insulin and other background glucose-lowering medication(s)
Inclusion: Diagnosed with T2DM for at least 90 days prior to screening; Stable treatment with background insulin and other background glucose-lowering medication(s); HbA1c value of ≥ 7% to ≤ 10.5%; Body mass index (BMI) of ≥ 23 kg/m2 at screening; Stable body weight (self-reported or documented) for 90 days prior to screening.
Exclusion: Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema; Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms; T1DM, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma; Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying; History of acute or chronic pancreatitis; Severe congestive heart failure (NYHA IV); History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.